FAMDF News Alert Futura Medical Plc (FAMDF) 0.7970 09/28/2014

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Futura Medical Plc (FAMDF) 0.7970 $FAMDF

Futura Medical plc - Product Pipeline Review - 2014
M2 - Thu Jul 24, 6:06AM CDT
Summary

Osteoarthritis Pain - Pipeline Review, H2 2013
M2 - Tue Sep 10, 3:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8frj9r/osteoarthritis) has announced the addition of the "Osteoarthritis Pain - Pipeline Review, H2 2013" report to their offering. 'Osteoarthritis Pain - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Osteoarthritis Pain, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Osteoarthritis Pain. Scope - A snapshot of the global therapeutic scenario for Osteoarthritis Pain. - A review of the Osteoarthritis Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Osteoarthritis Pain pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited and much more... For more information visit http://www.researchandmarkets.com/research/8f...oarthritis About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Erectile Dysfunction - Pipeline Review, H2 2013: An Overview of Pipeline Products for Erectile Dysfunction
M2 - Wed Sep 04, 9:38AM CDT
Research and Markets (http://www.researchandmarkets.com/research/l84sw4/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Erectile Dysfunction - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Erectile Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: - Acorda Therapeutics, Inc. - Chong Kun Dang Pharmaceutical - Dong-A Pharmaceutical Co., Ltd. - FCB-Pharmicell Co.,Ltd. - Fabre-Kramer Pharmaceuticals, Inc. - Futura Medical plc. - Global Health Ventures Inc. - IntelGenx Technologies Corp. - Medisyn Technologies, Inc. - NexMed, Inc. - NovaDel Pharma, Inc. - Palatin Technologies, Inc. - Sanofi-Aventis - Senetek PLC - VIVUS, Inc. - Yuhan Corporation For more information visit http://www.researchandmarkets.com/research/l84sw4/erectile About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Duchenne Muscular Dystrophy - Pipeline Review, H2 2013
M2 - Mon Sep 02, 9:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dxghnf/duchenne_muscular) has announced the addition of the "Duchenne Muscular Dystrophy - Pipeline Review, H2 2013" report to their offering. 'Duchenne Muscular Dystrophy - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Duchenne Muscular Dystrophy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Duchenne Muscular Dystrophy. Scope - A snapshot of the global therapeutic scenario for Duchenne Muscular Dystrophy. - A review of the Duchenne Muscular Dystrophy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Duchenne Muscular Dystrophy pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned Genzyme Corporation Johnson & Johnson Allergan, Inc. Amgen Inc. Sanofi-Aventis Eli Lilly and Company BioDelivery Sciences International, Inc. Pfizer Inc. Purdue Pharma L.P. Teva Pharmaceutical Industries Limited Menarini Group BioChemics, Inc. Addex Pharmaceuticals Elite Pharmaceuticals, Inc. POZEN Inc. Array BioPharma Inc. Futura Medical plc. Transition Therapeutics Inc. Palau Pharma S.A Neurotune AG QRxPharma Limited Iroko Pharmaceuticals, LLC and many more.... For more information visit http://www.researchandmarkets.com/research/dx...e_muscular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Male Sexual Dysfunction - Global Pipeline Review, H1 2013
M2 - Fri Jun 21, 5:15AM CDT
Research and Markets (http://www.researchandmarkets.com/research/44glgt/male_sexual) has announced the addition of the "Male Sexual Dysfunction - Pipeline Review, H1 2013" report to their offering. 'Male Sexual Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Male Sexual Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Male Sexual Dysfunction. Scope - A snapshot of the global therapeutic scenario for Male Sexual Dysfunction. - A review of the Male Sexual Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on

Erectile Dysfunction - Pipeline Review, H1 2013
M2 - Mon Mar 25, 9:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hp2gn2/erectile) has announced the addition of the "Erectile Dysfunction - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Erectile Dysfunction - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Erectile Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Erectile Dysfunction. Scope - A snapshot of the global therapeutic scenario for Erectile Dysfunction. - A review of the Erectile Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline proje

Premature Ejaculation - Pipeline Review, H1 2013
M2 - Thu Mar 21, 3:55AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tpptkh/premature) has announced the addition of the "Premature Ejaculation - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Premature Ejaculation - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Premature Ejaculation, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Premature Ejaculation. Scope - A snapshot of the global therapeutic scenario for Premature Ejaculation. - A review of the Premature Ejaculation products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipelin




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Kansas City Life Welcomes Kellie Needham to Board

Updated Category News Views 48

A New Era in Kansas City Life's Leadership This ain't your run-of-the-mill board appointment, folks. Kansas City Life Insurance Company has just handed the reins to Kellie S. Needham, who steps in to fill her mother's recently vacated board seat. Imagine that—a family legacy stretching back to the early 1900s when J.B. Reynolds first laid the foundation. Legacy Unbroken...

Continue Reading
Hehe Culture's Timeless Wisdom Explored at Forum

Updated Category News Views 0

Hehe Forum: Bridging the Past and Present Sometimes, the past isn't just anchor weight, it's a compass guiding us through the murky waters of today. The Hehe Culture Forum's latest gathering in Tiantai County, Zhejiang Province, aimed to unravel just how much ancient wisdom can still steer the course in this fast-changing world. Delegates from 23 nations joined forces,...

Continue Reading
Systemair Shakes Things Up: Closing Netherlands Facility

Updated Category News Views 81

Systemair's Shocking Shutdown Decision Feels like we're strapped into a roller coaster with these HVAC companies lately. Systemair (NASDAQ Stockholm: SYSR) sure gave us quite the surprise ride by announcing they're pulling the plug on their production facility in Waalwijk, the Netherlands. This isn't just a ripple in a pond; it's a splash that might make some waves in the...

Continue Reading
Are Shareholder Interests at Risk in These Deals?

Updated Category News Views 0

Potential Pitfalls in Pending Transactions In the tangled world of corporate deals, not every handshake benefits everyone around the table. This time, it's Surgery Partners, Range Resources, and Penske Automotive Group finding themselves under legal scrutiny. We'll dig into why Nasdaqq:SGRY, Nyse:RRC, and Nyse:PAG, might have some explaining to do. Whose Pockets Are...

Continue Reading
Barco Brings HDR Cinema Home with Kinepolis Kortrijk

Updated Category News Views 230

A New Chapter in Cinema Projection Ah, Belgium, the land of waffles and apparently, cutting-edge cinema tech. That's right, Barco is bringing their HDR by Barco system to its own backyard in Kortrijk, teaming up with Kinepolis to shake things up. It's not just any expansion—it's a homecoming of sorts. The company's laser cinema magic has already made face time in the...

Continue Reading
Food Emulsifiers Surge: Market to Hit $5.60B by 2031

Updated Category News Views 52

Forecasting Growth in Food Emulsifiers Picture this: the food emulsifiers market is steaming ahead, anticipating a thunderous boom from $4.43 billion in 2026 to a whopping $5.60 billion by 2031. According to recent estimates, that's a steady clip at a CAGR of 4.8%. If you're thinking that's just more industry chatter, let's peel back the layers and see what makes this...

Continue Reading
Landstar Faces Legal Storm Post Earnings Miss

Updated Category News Views 17

Landstar's Earnings Misstep Sends Shockwaves Alright, let's talk about this snafu at Landstar (NASDAQ: LSTR). They were supposed to deliver an earnings sheet that's all roses, but instead, we got a couple of thorns. Analysts were expecting them to strike gold with EPS numbers between $1.62 to $1.67. What we got? A measly $1.42. Not exactly the shiny haul we were led to...

Continue Reading
NeuroSense's Phase 3 Strategies for PrimeC Unveiled

Updated Category News Views 79

How NeuroSense Is Poised to Tackle ALS Treatment Picture this: a room full of people holding their breath, hoping that NeuroSense can deliver the breakthrough they’ve been inching toward. It’s the kind of moment that gives you goosebumps if you've been sloggin' through the biotech trenches. NeuroSense’s pitch at NEALS is more than just a dog and pony show—it's a...

Continue Reading
YSS Faces Legal Heat Over Misleading Investor Claims

Updated Category News Views 27

YSS Investors Navigate Legal Waters as Class Action Looms Taking a slug of coffee this morning and diving right into it—York Space Systems has found itself in hot water. They went public earlier this year with what was supposed to be a shining opportunity under the NYSE:YSS ticker, but it turns out that not everything in their IPO shined—and now SBS Law is stepping up...

Continue Reading
Why Haunted Attractions Keep Us Coming Back for Fear

Updated Category News Views 90

Welcome to Fear Incarnated Ah, Kansas City. More than just jazz and barbeque. You’ve got these infamous haunted houses that turn every horror flick into a mere Saturday morning cartoon. Enter Edge of Hell and Beast Haunted Attraction. Two horrifying museums of fear that somehow lure us like flies to sugar from miles away. What's the secret sauce? Well, that’s half the...

Continue Reading

Top 5 Most Recently Viewed Articles

Artiva Biotherapeutics Highlights Participation in Key Conference

Updated Category News Views 166

Artiva Biotherapeutics to Showcase at Annual Health Care Conference Artiva Biotherapeutics, Inc. (NASDAQ: ARTV), a pioneering clinical-stage biotechnology firm, is set to make a significant presence at the TD Cowen 45th Annual Health Care Conference. The event will be held on a Wednesday in the near future, featuring Artiva’s management team who will deliver a...

Continue Reading
Propel Holdings Achieves Remarkable Growth and Dividend Boost

Updated Category News Views 212

Propel Holdings Reports Impressive Financial Results Propel Holdings Inc. (TSX: PRL) has achieved remarkable financial results in its latest quarter, marked by record revenue and an increase in its dividend, showcasing its commitment to supporting underserved consumers. The fintech company, which operates various brands and platforms, has successfully navigated a...

Continue Reading
Ladder Capital Corp's Q3 2024 Financial Performance Revealed

Updated Category News Views 81

Ladder Capital Corp Reports Strong Q3 2024 Financial Results Ladder Capital Corp (NYSE: LADR) has announced its operating results for the quarter that recently concluded. The company reported a GAAP income before taxes of $28.5 million during this period, resulting in a diluted earnings per share (EPS) of $0.22. Additionally, Ladder achieved $37.7 million in distributable...

Continue Reading
IQSTEL Achieves $57.6M in Q1 Revenue, Eyes $1 Billion by 2027

Updated Category News Views 183

IQSTEL Reports Robust Q1 Revenue Performance IQSTEL Inc. (NASDAQ: IQST), a leading multinational technology and telecommunications provider, recently unveiled its Q1 revenue results. The company earned an impressive $57.6 million, showcasing a 12% year-over-year increase, as mentioned in its inaugural NASDAQ shareholder letter. A Vision for $1 Billion Revenue CEO Leandro...

Continue Reading
WesBanco's Growth Boosted by Successful Premier Acquisition

Updated Category News Views 223

WesBanco's Ambitious Expansion Strategy WesBanco, Inc. (NASDAQ: WSBC), a leading financial services provider, has recently undertaken a significant step in enhancing its regional presence. This transformation comes with the successful integration of Premier Financial Corp.'s approximately 400,000 consumer and 50,000 business accounts into its operations. This is a...

Continue Reading